Clinical Handbook of Psychotropic Drugs
- Indbinding:
- Paperback
- Sideantal:
- 474
- Udgivet:
- 13. juli 2021
- Udgave:
- 21024
- Størrelse:
- 242x35x284 mm.
- Vægt:
- 1501 g.
- Ukendt - mangler pt..
Normalpris
Abonnementspris
- Rabat på køb af fysiske bøger
- 1 valgfrit digitalt ugeblad
- 20 timers lytning og læsning
- Adgang til 70.000+ titler
- Ingen binding
Abonnementet koster 75 kr./md.
Ingen binding og kan opsiges når som helst.
- 1 valgfrit digitalt ugeblad
- 20 timers lytning og læsning
- Adgang til 70.000+ titler
- Ingen binding
Abonnementet koster 75 kr./md.
Ingen binding og kan opsiges når som helst.
Beskrivelse af Clinical Handbook of Psychotropic Drugs
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.
Independent, unbiased, up-to-date
Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug
Potential interactions and side effects summarized in comparison charts
With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
New in this edition
Neuroscience-based nomenclature - added to product availability tables
Antidepressants chapter includes new section on GABAA receptor positive modulator (brexanolone IV injection; trade name Zulresso); also covers Qelbree (viloxazine extended-release capsules), the first new ADHD medication approved by the FDA in over a decade; as well as updates to SSRI use in pregnancy and antidepressant augmentation strategies
Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment
Mood stabilisers chapter sections on lithium and anticonvulsants extensively revised
New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta (lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection), Qelbree (viloxazine extended-release capsules)
Independent, unbiased, up-to-date
Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
Succinct, bulleted information on all classes of medication: on- and off-label indications, (US FDA, Health Canada), recommended dosages, US and Canadian trade names, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug
Potential interactions and side effects summarized in comparison charts
With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
Clearly written patient information sheets available for download as printable PDF files
This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.
New in this edition
Neuroscience-based nomenclature - added to product availability tables
Antidepressants chapter includes new section on GABAA receptor positive modulator (brexanolone IV injection; trade name Zulresso); also covers Qelbree (viloxazine extended-release capsules), the first new ADHD medication approved by the FDA in over a decade; as well as updates to SSRI use in pregnancy and antidepressant augmentation strategies
Antipsychotics updates include revised dosing, especially adjustments in hepatic and renal impairment
Mood stabilisers chapter sections on lithium and anticonvulsants extensively revised
New formulations and trade names include: Adhansia XR (methylphenidate extended-release capsules), Caplyta (lumateperone), Dayvigo (lemborexant), Perseris (risperidone extended-release subcutaneous injection), Probuphine (buprenorphine subdermal implant), Propecia (finasteride tablets), Trelstar (triptorelin slow-release injection), Qelbree (viloxazine extended-release capsules)
Brugerbedømmelser af Clinical Handbook of Psychotropic Drugs
Giv din bedømmelse
For at bedømme denne bog, skal du være logget ind.Andre købte også..
Find lignende bøger
Bogen Clinical Handbook of Psychotropic Drugs findes i følgende kategorier:
© 2025 Pling BØGER Registered company number: DK43351621